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Abstract C3 glomerulopathy (C3G) is a recently identified
disease entity caused by dysregulation of the alternative
complement pathway, and dense deposit disease (DDD) and
C3 glomerulonephritis (C3GN) are its components. Because
laboratory detection of complement dysregulation is still
uncommon in practice, ‘‘dominant C3 deposition by two
orders greater than that of immunoglobulins in the glomeruli
by immunofluorescence’’, as stated in the consensus report,
defines C3G. However, this morphological definition pos-
sibly includes the cases with glomerular diseases of different
mechanisms such as post-infectious glomerulonephritis. In
addition, the differential diagnosis between DDD and C3GN
is often difficult because the distinction between these two
diseases is based solely on electron microscopic features.
Recent molecular and genetic advances provide information
to characterize C3G. SomeC3G cases are foundwith genetic
abnormalities in complement regulatory factors, but major-
ity of cases seem to be associated with acquired factors that
dysregulate the alternative complement pathway. Because
clinical courses and prognoses among glomerular diseases
with dominant C3 deposition differ, further understanding
the background mechanism, particularly complement dys-
regulation in C3G, is needed. This may resolve current
dilemmas in practice and shed light on novel targeted
therapies to remedy the dysregulated alternative comple-
ment pathway in C3G.
Keywords C3 glomerulopathy  Dense deposit disease 
C3 glomerulonephritis  Membranoproliferative
glomerulonephritis  Alternative complement pathway 
Dominant C3 deposition
Introduction
C3 glomerulopathy (C3G) is an emerging kidney disease
caused by dysregulation of the alternative complement
pathway [1–5]. The characteristic pathology of this disease
is glomerular depositions of dominant C3 with absent or
weak immunoglobulins [6, 7]. Therefore, C3G is basically
diagnosed by immunofluorescence (IF) and it can reveal
various patterns of glomerular injuries by light microscopy
(LM) [6, 7].
Following the recent trend of pathogenesis-based reclas-
sification of glomerular diseases, glomerulonephritis asso-
ciated with alternative complement dysregulation is
collectively referred to as C3G [1, 8]. Because laboratory
detection of alternative complement dysregulation is still
uncommon in current practice, predominant C3 deposition
by IF is an initial finding that suggests C3G. However,
glomerular diseases caused by mechanisms other than
alternative complement dysregulation may occasionally
satisfy ‘‘C3-dominant deposition with scanty immunoglob-
ulins’’ as stated in the current consensus report [6]. Post-
infectious glomerulonephritis (PIGN) is an immune com-
plex-mediated glomerulonephritis that sometimes displays
dominant C3 deposition by IF [9]. In addition, differential
diagnosis between two variants of C3G, dense deposit dis-
ease (DDD) and C3 glomerulonephritis (C3GN), is
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necessary if they show different clinical courses and treat-
ment responses. DDD is highlighted by dense osmiophilic
intramembranous deposition by electron microscopy (EM),
and C3GN is diagnosed when it lacks such characteristics
seen in DDD [6]; nevertheless, the distinction between these
two diseases is often difficult [6, 10]. Clearly, pathogenesis-
based classification in glomerular diseases is an important
prospect for appropriate therapies, but the entity of C3G still
presents dilemmas in diagnostic practice by lack of clear
definition and pathogenic basis.We review the current status
of C3G and dilemmas that may bring a more distinct defi-
nition and accurate therapies for patients with alternative
complement dysregulation.
MPGN and C3 glomerulopathy
The idea of C3G seems to be derived from inconsistent
clinicopathological features of membranoproliferative
glomerulonephritis (MPGN). MPGN was described ini-
tially by hypocomplementemia-associated glomeru-
lonephritis characterized by glomerular capillary wall
thickening with hypercellularity in the glomerular tuft
[11]. MPGN is basically a LM-based disease entity and
became subclassified into three types by the location of
electron-dense deposits. Dense deposits in MPGN type I
present mainly in the subendothelial spaces [12]. In
contrast, those in MPGN type II/DDD are found in the
lamina densa with characteristic highly dense, continu-
ous features and often seen in other glomerular com-
partments [12, 13]. MPGN with a combination of
subepithelial, subendothelial, and intramembranous
deposits was classified as MPGN type III, which was
further subclassified into two forms: the Burkholder
variant and the Strife and Anders variant [14–16].
Inconsistent IF patterns among three types of MPGN
may be one of the background ideas of C3G.
Immunofluorescent findings revealed variety of patterns
and were inconsistent even in one subtype. MPGN type I
generally reveals granular or fringe patterns of IgG and
C3 deposits along the capillary loop [17]. In DDD,
however, most cases exhibit isolated or dominant C3
deposition with linear or granular patterns in the
mesangium and in the capillary loops [17–19]. On the
other hand, some studies have reported segmental
immunoglobulin deposition in about half of the cases
with DDD [20, 21]. In MPGN type III, IF typically
shows granular IgG and C3 depositions in the Bur-
kholder variant [14], whereas it shows dominant C3
deposition with or without IgG in the Strife and Anders
variant [15]. In fact, 8% of MPGN type I cases and
10.4% of MPGN type III cases, mostly the Strife and
Anders variant, showed isolated C3 deposition [21]. This
deposit-based subclassification by EM together with IF
has suggested distinct pathogenic mechanisms underly-
ing some cases with MPGN, the dysregulated alternative
complement pathway.
Alternative complement pathway
The complement system plays a crucial role in innate
immunity and augments immune effectors in acquired
immunity by antibody removal, recruitment and activation
of leukocytes, phagocytosis, and cell membrane lysis via
membrane attack complex. Complement activation occurs
through the classical, lectin, and alternative complement
pathways, and the cleavage of C3 plays a common and key
role in the effector functions for all the pathways [22].
Activation of the alternative complement pathway is
uniquely initiated by the spontaneous hydrolysis of C3
called ‘‘tick-over’’, and it occurs continuously at low levels
in ordinary states [22]. There are several complement
regulatory mechanisms in plasma and on cell surfaces to
keep its activation at low levels because overactivation of
the complement system can lead to injury of our own cells
and tissues as attacking principle pathogens [22, 23].
Several factors that regulate the complement function are
called complement regulatory factors (CRFs), including
complement factor H (CFH), complement factor H-related
proteins (CFHR), complement factor I (CFI), membrane
cofactor protein (MCP), and complement factor B (CFB)
[22, 23]. They regulate the complement activation in
plasma ‘‘fluid phase activation’’ and on cell surface ‘‘solid
phase activation’’ [23]. CFH is the key regulator of the
alternative complement pathway mainly in fluid phase by
accelerating C3 convertase decay. CFH and CFHR genes
share high homology in their DNA sequences, and their
proteins interact to stabilize the complement pathway. CFI
is a serine protease in the serum that cleaves C3b and C4b
in the presence of cofactors, such as MCP which is a cell-
surface complement regulator. CFB binds C3b and stabi-
lizes C3 convertase [22, 23]. Dysfunction of CRFs pro-
motes amplification of C3b, leading to alternative
complement overactivation as discussed in the following.
Alternative complement dysregulation in C3
glomerulopathy
History of the detection of alternative complement
dysregulation in DDD
In 1963, Berger et al. first described DDD as a glomeru-
lonephritis with unique and extremely osmiophilic elec-
tron-dense deposits in glomerular basement membrane
(GBM) [24]. In the early 1970s, DDD was reported as an
anomaly of GBM among MPGN cases [13]. The compo-
sition of this peculiar intramembranous deposition in DDD
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has long been a mystery. The intramembranous electron-
dense substance in DDD was first considered to be an
accumulation of glycoprotein membrane material. This was
merely speculation based on the increase of sialic acid and
the lack of immunoglobulins in membrane solution
according to the analysis by electrophoresis [25].
As some patients with DDD also develop extrarenal
manifestations such as ocular drusen, acquired partial
lipodystrophy (APL), and diabetes mellitus type 1, DDD
was once regarded as a glomerular disease associated with
metabolic disorders [26]. Ocular drusen are whitish-yellow
deposits of lipoproteins within the Bruch membrane
beneath the retinal pigment epithelium, and complement
complexes such as C5b-9 were identified in drusen asso-
ciated with aging and other glomerulonephritis [27]. APL
is a condition with permanent loss of adipose tissue from
face and upper body, and often accompanied by low serum
C3 levels and the presence of C3NeF. Adipose tissue
produces some CRFs, and the activated complement
pathway contributes to the deposition of complement
components, resulting in the destruction of adipocytes in
APL [28]. These disease associations suggested that a
subset of DDD was mediated by systemic complement
dysregulation.
Dysregulation of the alternative complement pathway
in DDD was established by the detection of complement
components in the glomeruli in situ and auto-antibodies
in the serum. Complement component 3 nephritic factor
(C3NeF), an auto-antibody to C3 convertase which was
originally identified in the serum of cases with
hypocomplementemic glomerulonephritis by quantitating
C3 breakdown using an immunoprecipitation method
[29], is detected in the serum in approximately 80% of
cases with DDD [30]. Moreover, using mass spectrom-
etry in the glomeruli of DDD, Sethi and co-workers
could not detect CFB components despite the presence
of alternative pathway component (C3), terminal com-
plement complex (C5b-9), and its two fluid phase reg-
ulators: clusterin and vitronectin [31]. This suggests that
the major site of alternative complement activation in
DDD is in the fluid phase and subsequent inactive
complement complex accumulates in the glomeruli.
Mechanism of complement dysregulation in C3
glomerulopathy
Excessive activation of the alternative complement path-
way and amplification of C3b due to an inherited defect
and/or acquired dysfunction of CRFs is considered to be
the pathogenesis of C3G (Fig. 1) [23, 30]. By genetic
analysis, several mutations including those in CFH, CFHR,
CFI, MCP, C3, and CFB have been identified in patients
with C3G [32–38]. The mutations in CRFs lead to loss of
function in CFH, CFI, and MCP or gain of function in C3
and CFB, resulting in overactivation of the alternative
complement pathway.
Acquired factors also promote C3b amplification. As
mentioned above, C3NeF is a well-known auto-antibody
against the C3 convertase (C3bBb) that cleaves C3 into C3a
and C3b. C3NeF stabilizes C3bBb and prevents the inhi-
bitory actions of CRFs, resulting in uncontrolled C3 acti-
vation and low serum C3 levels [29]. However, because
C3NeF production is also found in other types of glomerular
diseases and even in healthy individuals [39, 40], additional
factors such as infections may trigger C3NeF activation
involved in the development of C3G.
In addition to C3NeF, hyper-production of monoclonal
immunoglobulins (MIGs) that attack CRFs in
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Fig. 1 Schema illustrates the complement cascade and CRFs of the
alternative pathway in C3G. The key events in C3G in this cascade
include abnormal amplification of C3b production by activation of C3
to C3b through the following pathways. (1) Accelerated forming
C3bBb by CFB through gain of function. Activation of C3b
convertase by (2) dysfunction of CFH which degrades C3bBb, (3)
enhancing CFH deregulation by dysfunction of CFHR, or (4)
production of C3NeF which inhibits the degradation of C3bBb. (5)
Suppression of C3b inactivation by CFH/CFI/MCP/CFHR also
amplifies C3b activation. This dysregulation of CRFs may be caused
not only by inherited mutations in the genes responsible for these
factors but also in acquired factors such as auto-antibodies for CRFs
and C3NeF. CFH complement factor H, CFI complement factor I,
CFHR complement factor H-related proteins, MCP membrane
cofactor protein, CFB complement factor B, C3NeF complement
component 3 nephritic factor
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hematological disorders underlies C3G as another acquired
factor. The glomerulonephritis associated with monoclonal
gammopathy generally reveals MPGN by LM and C3
deposition with or without immunoglobulins by IF [41–44].
MIGs potentially activate the classical pathway directly or
amplify the alternative complement pathway, depending on
the function of the aberrantly synthesized MIGs [41].
Because mass spectrometry for glomerular tissue in C3G
cases associated with monoclonal gammopathy identified
components of the alternative complement pathway in the
glomeruli [42], and an anti-CFH antibody or C3NeF was
detected occasionally in the serum [42, 43], MIGs may act
as auto-antibodies to protect degradation of C3 convertase,
which finally activates C3 amplification loop (Fig. 1). One
study analyzing 14 adult cases with DDD found monoclonal
gammopathy of undetermined significance (MGUS) in 71%
of them [43]. Thus, monoclonal gammopathy needs to be
considered as a possible cause of C3G.
Differences in alternative complement dysregulation
between DDD and C3GN
Although both DDD and C3GN are driven similarly by
alternative complement dysregulation, the distinct patho-
physiological mechanisms underlying each disease are still
unknown. Zhang et al. reported higher C3NeF activity in
DDD than in C3GN, whereas soluble C5b-9 was higher in
C3GN than in DDD [45]. Medjeral-Thomas et al. demon-
strated that DDD presented more crescentic glomeru-
lonephritis, at younger ages, lower serum C3 levels, and
with greater predisposition to end-stage renal disease
(ESRD) compared with C3GN [46]. These data suggest that
DDD can be caused by earlier components dysregulated at
C3 levels, whereas dysregulation in C3GN occurs in the
late/terminal components of the alternative complement
pathway. The different mechanisms between these two
diseases may explain the more aggressive course in DDD
than in C3GN.
Current detection of alternative complement dysregulation
in C3 glomerulopathy
Practically, the inherited and/or acquired defects behind
alternative complement pathway dysregulation have been
identified only in a subset of patients with C3G. Servais
et al. reported CFH, CFI, or MCP mutations in 17.2% of
cases with DDD and in 19.6% of those with C3GN [32],
suggesting that the majority of C3G cases do not possess
genetic mutations in CRFs. In addition, C3NeF is not
detected in approximately 20% of cases with DDD and in
more than half with C3GN [32].
Based on the pathogenesis assumed in this disease,
biochemical analysis for the alternative complement
pathway is desirable to diagnose C3G [47]. It includes
functional analysis based on hemolytic assays, quantifica-
tion of complement components and CRFs, and measure-
ment of complement activation markers such as C3 decay
products and soluble C5b-9 [47]. These technologies will
hopefully be available for every patient with predominant
C3 deposition in the glomeruli.
Alternative complement dysregulation in animal models
A causal relationship between genetic abnormalities in
CRFs and glomerular pathology has been demonstrated in
animal models with genetic defects in CRFs. In CFH-de-
ficient piglets and mice, activation of the alternative com-
plement pathway resulted in low serum C3 levels [48–50].
In these models, glomeruli showed the MPGN pattern with
linear C3 and subendothelial/intramembranous deposits,
which correspond to human C3G. Such unique models may
provide further understanding of the mechanisms of C3
deposition and lead to potential therapies for C3G.
Clinical features and prognosis in C3
glomerulopathy
Clinically, most of the cases with C3G present proteinuria
and hematuria [46]. The cases of 6.9% in DDD and 16.1%
of C3GN present nephrotic syndrome [32]. Low serum C3
levels are found in 59–79% of DDD and 40–48% of C3GN
[32, 46]. DDD is often diagnosed in childhood, whereas
C3GN is usually developed at older age than DDD [46].
The long-term renal prognosis of C3G is generally
unfavorable. It was reported that 47% of 17 patients with
DDD and 23% of 53 patients with C3GN progressed to
ESRD during a median follow-up period of 28 months
[46]. In addition, the recurrence of C3G after renal trans-
plantation occurs frequently resulting in graft loss: 50% in
DDD, 43% in C3GN [46].
Histopathology of C3 glomerulopathy
C3G reveal various histological patterns of glomerular injury
by LM, including mesangial proliferative, diffuse endocap-
illary proliferative, and crescentic glomerulonephritis
[7, 19, 20]. This indicates that discrimination of C3GN and
DDD is difficult by LM, except in cases with the typical
features of DDD such as intensely Periodic acid-Schiff (PAS)
staining positive, ribbon-like intramembranous deposits with
thickened GBM [13, 51]. These unique deposits also show
lack of methenamine silver staining (Fig. 2), fuchsinophilic
(red) in trichrome staining, dark blue with toluidine blue, and
positive for the thioflavin T [51, 52].
IF findings of C3G were defined initially as isolated C3
deposition [1], but the deposition of C3 is not always
544 Clin Exp Nephrol (2017) 21:541–551
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‘‘isolated’’. According to the current consensus report, the
term ‘‘isolated’’ was replaced by ‘‘dominant staining of C3
defined as at least two orders of C3 intensity greater than
that of any other immune reactant’’ [6]. This extended
definition was derived from the fact that 47.6% of DDD
cases show various amounts of glomerular immunoglobu-
lin deposits even though they are caused by alternative
complement activation [21]. More studies are needed to
explain the immunoglobulin depositions in DDD, particu-
larly on the initial immune reaction that induces alternative
complement dysregulation.
Diagnostic dilemmas in C3 glomerulopathy
The entity of C3G is rational, but it still presents some
diagnostic dilemmas in practice. Given that C3G is defined
by predominant glomerular C3 deposition (two orders
greater than immunoglobulins), other glomerulonephritis
types, particularly those that are immune complex-medi-
ated, occasionally fit this criterion, too. Table 1 summa-
rizes the clinical and histopathological features of DDD
[5, 32, 46, 52–56], C3GN [5, 32, 46, 52, 57], and PIGN
[52, 58–61].
C3G versus PIGN
PIGN is a distinct immune complex-mediated glomeru-
lonephritis caused by antibodies against infectious
microbes [58]. Because diseases in this category generally
have favorable prognoses, they should be distinguished
from C3G. The difficulty with the differential diagnosis in
this case may be explained by the following considerations.
First, PIGN is an immune complex-mediated glomeru-
lonephritis, but it sometimes shows isolated C3 deposition
Fig. 2 Representative
glomerular features of DDD and
C3GN by light microscopy
(LM) and electron microscopy
(EM). DDD by LM (a) shows
thickened glomerular basement
membrane (GBM) stained
negatively with methenamine
silver, giving pink color with
hematoxylin. In C3GN, LM
(b) reveals irregular GBM with
double contours stained on the
background of mesangial
proliferation. By EM, a highly
electron-dense deposition
replaces the lamina densa of
GBM (c) in DDD, whereas
C3GN shows thickened GBM
with mottled and less
osmiophilic deposits versus
those of DDD (d)
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without immunoglobulins, particularly during the post-
acute phase [9]. The mechanism of isolated C3 deposition
during the late phase of PIGN has been suggested to be
persistent C3 amplification, while the deposition of IgG
drops to undetectable levels [62]. Second, the presence of
the ‘‘hump’’, the characteristic deposition of PIGN, is not
specific but is often seen in other glomerulonephritis types
including MPGN and C3G [7], and it disappears during the
later phase of PIGN [63]. Third, C3G occasionally shows
endocapillary proliferative glomerulonephritis similar to
PIGN [6, 7, 46, 57]. Conversely, PIGN can show expansion
of the lobules, hypercellularity of the tuft, and thickening
of the glomerular capillary walls mimicking MPGN [60].
Finally, some cases with PIGN reveal prolonged protein-
uria and low serum C3 levels that clinically and patho-
logically represent chronic glomerulonephritis similar to
C3G [9]. The IF pattern alone is insufficient to discriminate
whether a faint deposit of IgG is an immune complex or
not. In this regard, glomerular staining of C4d, a byproduct
of activation of the classical and lectin pathways, may be
useful for the identification of an immune complex-medi-
ated mechanism [64].
Interestingly, recent reports suggested the transforma-
tion of PIGN to C3G by repeat biopsies [65–68]. In this
context, there are several possibilities, including (1) the
transformation of PIGN to C3G, (2) similar appearances of
early lesions of C3G and PIGN, and (3) initiation of C3G
by streptococcal infection. Sethi et al. described that most
of the cases with biopsy-proven PIGN presenting persistent
hematuria and proteinuria had underlying defects with
genetic mutations and/or auto-antibodies affecting regula-
tion of the alternative complement pathway [9]. In addi-
tion, several reports have demonstrated the presence of
nephritis-associated plasmin receptor (known as NAPlr), a
nephritogenic antigen for post-streptococcal acute
glomerulonephritis, in cases with C3G [65, 69, 70]. These
findings indicate that glomerular injuries initiated by
infection may transfer to C3G by switching activation of
the alternative complement pathway. It may be surmised
that C3G is initiated by heterogeneous insults, leading to a
final common pathway of alternative complement dysreg-
ulation. Clearly, more studies and case observations are
necessary to determine the mechanism of C3G and to
identify critical differential tools to discriminate it from
PIGN.
DDD versus C3GN
The distinction between DDD and C3GN is also sometimes
difficult [6, 10]. Patterns of IF in these two diseases are
often similar and provide little basis for discrimination. In
fact, glomerulonephritis with ‘‘dominant staining of C3
defined as at least two orders of C3 intensity greater than
that of any other immune reactant’’ without DDD-like
deposits by EM is automatically classified as C3GN.
Electron-dense deposits of C3GN are generally less dense,
less well defined, and more amorphous than those of DDD.
In addition, these deposits are found in subendothelial and
mesangial regions as well as occasionally in intramem-
branous and subepithelial regions as seen in DDD [7].
Ultimately, the density and pattern of the intramembranous
dense deposits are the critical differences between C3GN
and DDD. In this regard, we may diagnose atypical or
incipient DDD as C3GN when it lacks DDD-like deposits.
The reason for the different density and pattern of electron-
dense deposits remains unclear. One of the reasons may be
speculated that components other than complement system
can exist in depositions in DDD, such as previously sug-
gested metabolic substances. Although it is still unknown
whether C3GN transforms to DDD or vice versa, a few
reports have described that the early pathology of recurrent
DDD in renal transplantation, showing isolated C3 depo-
sition without DDD-like EM features which was corre-
sponding to C3GN [71, 72], developed into typical DDD in
repeat biopsies [71]. If some cases of DDD and C3GN are
in different stages of the same disease, there should be
intermediate cases that are more difficult to be diagnosed
(Fig. 3). It may be possible that undetermined cases of
C3G represent different stages of the same disease, and it
would be better to incorporate DDD and C3GN into the
same category of ‘‘alternative complement-mediated
glomerulonephritis’’ on the basis of common pathogenesis.
Apparently, molecular or genetic markers to discriminate
DDD and C3GN are necessary if these two diseases have
different pathogenesis. The current concept of C3G is
summarized in Fig. 4, and the pathogenesis of this disease
can be a base of the therapies.
Therapeutic prospects for C3 glomerulopathy
In current practice, the main treatments for C3G are
immunosuppressive and supportive therapies. C3G is a
heterogeneous disease entity with various pathogenic
mechanisms that commonly cause alternative complement
dysregulation [30]. Whatever the causative factors are,
immunosuppressive therapies are appropriate because of
the inflammatory nature of this glomerular disease. In
addition, immunosuppression may also be effective in C3G
cases associated with auto-antibodies for complement
components or CRFs such as C3NeF. As immunosup-
pressant drugs, corticosteroids [73, 74], cyclophosphamide
[75, 76], mycophenolate mofetil (MMF) [77], and ritux-
imab [78, 79] have been used for C3G. Plasma exchange
can benefit patients with C3G by removing auto-antibodies
or mutant proteins and replacing normal CRFs [80–83].
However, the efficacy of such immune modulations and
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conventional therapies has been limited and direct blocking
of C3 amplification loop is needed for C3G. Although the
mechanism is not related to remedy of complement dys-
regulation, inhibitors of renin-angiontensin system are the
only recommended agents for C3G due to the association
with better renal survival [32].
Eculizumab can be a modern therapy against C3G that
acts by inhibiting the alternative complement overactivation.
This new agent is a humanizedmonoclonal anti-C5 antibody
and prevents C5 cleavage into C5a, a chemotactic agent and
an anaphylatoxin, and C5b, one of the components of
membrane attack complex (C5b-9) [84]. Several cases of
C3G treated with eculizumab have been reported recently,
but its efficacy has been limited only in a subset of them
[79, 85–88]. One of the reasons for inconsistent efficacy is
speculated that eculizumab basically blocks the terminal
pathway by inhibiting the formation of membrane attack
complex, and might be ineffective particularly for the
patients with C3G more involved by activation of the upper
pathway. On the other hand, some cases with C3G treated
with eculizumab revealed the reduction of glomerular C3
deposition, suggesting that C5a blocking may lead to
resolving the upper pathway activation through the decrease
of glomerular inflammation in such cases. In addition to
C3NeF synthesized by autoimmune mechanisms, MIGs
overproduced in hematological disorders attack CRFs,
leading to C3G [41]. In this case, therapy for monoclonal
gammopathy is a principle to halt the amplification loop.
Fig. 3 Pediatric case with low
serum C3 levels over five years
showing the MPGN pattern by
light microscopy (a Periodic
acid-Schiff stain and b Periodic
acid-methenamine silver stain)
with isolated granular C3
deposition by
immunofluorescence (middle
panels). Electron microscopy
shows mesangial and
intramembranous deposits that
are not very dense (c), as
usually seen in DDD (Fig. 1). In
a portion, intramembranous
continuous deposition with
moderate density was seen (d).
This case was presented at
international conferences, and
there were inconsistent
diagnoses among renal
pathologists. Abnormalities of
complement factors are under
investigation
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At present, there are still many missing pieces that must
be assembled to determine pathophysiology-based thera-
pies for C3G, and further investigations are certainly
warranted.
Conclusions
C3G is a novel and rational disease classification based on the
pathogenesis of the dysregulated alternative complement
pathway. However, it is still a tentative category including
glomerular diseases of variable morphologies, stages, and
pathophysiologies, resulting in some diagnostic dilemmas.
We need to solve these dilemmas to bring the promise of
rational diagnosis and pathogenesis-based therapies to the
bedside.
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